Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Daratumumab Or Darzalex Market Value Growth And Long-Term Outlook
The market size for daratumumab or darzalex has experienced rapid growth in recent years. It is projected to expand from $5618.3 million in 2025 to $6189.36 million in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. This historical growth is attributable to its approval for multiple myeloma treatment, strong clinical outcomes specifically targeting CD38, the limited availability of alternative treatments for relapsed disease, widespread adoption by oncology centers, and improved patient survival rates.
The market for daratumumab or darzalex is projected to experience substantial expansion over the coming years. Its valuation is set to reach $9024.5 million by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This anticipated growth during the projection period stems from factors such as the broadening of combination treatments, an increasing incidence of multiple myeloma, greater investment in oncology, the emergence of novel indications, and enhanced patient access initiatives. Key trends during the forecast horizon encompass a surge in its uptake for multiple myeloma, its synergistic application with other cancer medications, its integration into earlier stages of treatment, the administration of monoclonal antibody therapy within hospital settings, and its increasing application in various hematologic malignancies.
Get A Free Sample Report With In-Depth Market Insights:
Daratumumab Or Darzalex Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of bone marrow cancer is anticipated to fuel the expansion of the daratumumab or darzalex market. These cancers originate in the bone marrow, exemplified by multiple myeloma and leukemia, where the irregular production of blood cells interferes with normal bodily functions. This growing incidence is linked to an aging demographic, enhanced diagnostic techniques, and other factors such as environmental exposures, lifestyle choices, and genetic predispositions. Daratumumab (Darzalex) addresses multiple myeloma, a form of bone marrow cancer, by specifically targeting and eliminating abnormal plasma cells found within the bone marrow. For instance, in January 2025, the American Cancer Society, a US-based non-profit organization, projected that 2025 would see around 3,770 new cases of primary bone and joint cancer (2,150 in men and 1,620 in women), alongside approximately 2,190 fatalities (1,240 in men and 950 in women). Consequently, the heightened incidence of bone marrow cancer is a key factor propelling the growth of the daratumumab or darzalex market.
Daratumumab Or Darzalex Market Segment Trends And Revenue Contributors
The daratumumab or darzalex market covered in this report is segmented –
1) By Drug Type: 100Mg Injection, 400Mg Injection
2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels
3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications
Daratumumab Or Darzalex Market Trends Redefining Industry Growth
Entities operating in the daratumumab or darzalex market are increasingly shifting their focus in oncology treatments towards early intervention strategies, particularly combination therapies, to boost the efficacy of treating multiple myeloma and other cancers. Combination therapies are defined as treatment methodologies that employ two or more therapeutic agents with varied mechanisms of action, frequently working synergistically to elevate effectiveness, minimize resistance, and enhance patient outcomes, potentially leading to fewer adverse effects when compared to single-agent therapy. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) used in conjunction with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the induction and consolidation phases of therapy in patients with newly diagnosed multiple myeloma (NDMM) who qualify for autologous stem cell transplant (ASCT). This new clearance introduces a quadruplet therapy option available at the initial diagnosis, with the potential to improve patient outcomes.
Daratumumab Or Darzalex Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.
View The Full Daratumumab Or Darzalex Market Report:
Daratumumab Or Darzalex Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
